Genocea Biosciences (GNCA) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. ZETA
9. DAL
10. TMUS

Go back to Genocea Biosciences (GNCA) Tops Q4 EPS by 1c

Genocea Provides Fourth Quarter 2021 Corporate Update

March 10, 2022 7:00 AM EST

Initial GEN-011 clinical trial data to be presented at AACR

Conference call today at 8:30 a.m. ET

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021.

GEN-011 TiTAN trial update

Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted... More